MFN2 and leukemia: Our subsequent data show that both MFN-2 and OXPHOS respiratory complexes are significantly upregulated in surviving leukemia cells, and that MFN-2 knockout substantially increases Jurkat sensitivity to DxR, providing a potential target for increasing chemotherapy efficacy and reduction of side effects.